Trastuzumab associated cardiac adverse effects in breast cancer

Abstract

Abstract: Trastuzumab has been used widely for the treatment of women with human epidermal growth factor receptor-2(HER2) overexpressing breast cancer in the early and advanced disease. However, cardiac toxicity has emerged as a rare but potentially serious risk that limits its therapeutic potential in a subset of women.Asymptomatic decreasing left ventricular ejection fraction (LVEF) was a common complication and generally reversible and manageable.The increasing risk of trastuzumab-induced cardiac toxicity may be influenced by factors such as age, hypertension and the use of anthracyclines-based chemotherapy.Rigorous cardiac monitoring should be performed for all patients receiving trastuzumab currently in clinic.

Key words: Breast cancer, Trastuzumab, Cardiac toxicity, Targeted therapy

CLC Number:

R737.9

SHENG Li-ming, DU Xiang-hui. Trastuzumab associated cardiac adverse effects in breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1077-1080.

References

[1] Cuadros M, Cano C, López FJ, et al. HER2 status in breast cancer: experience of a Spanish National Reference Centre [J]. Clin Transl Oncol, 2011, 13(5): 335-340.
[2] 赵文英, 吴万春. 心理危机干预改善晚期乳腺癌患者生活质量的研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 101-105.
[3] Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial [J]. J Clin Oncol, 2009, 27(36): 6129-6134.
[4] Slamon D, Eiermann W, Robert NPT, et al. BCIRG 006 Phase III Trial Comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis [J]. Cancer Res, 2009, 29: abstract 62.
[5] Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial [J]. J Clin Oncol, 2008, 26(8): 1231-1238.
[6] Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide(AC)→paclitaxel(T) vs. AC→T with trastuzumab(H) [J]. J Clin Oncol, 2007, 25(18S): LBA513.
[7] Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial [J]. J Clin Oncol, 2007, 25(25): 3859-3865.
[8] Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis [J]. Cancer Treat Rev, 2011, 37(4): 312-320.
[9] 韦劲松, 李志革, 宋向群, 等. Herceptin联合化疗治疗Her2过度表达的转移性乳腺癌的初步观察[J]. 中国癌症防治杂志, 2010, 2(1): 22-24.
[10] Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation [J]. Basic Res Cardiol, 2005, 100(3): 240-249.
[11] Chien KR. Herceptin and the heart--a molecular modifier of cardiac failure [J]. N Engl J Med, 2006, 354(8): 789-790.
[12] Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues [J]. Expert Opin Biol Ther, 2008, 8(12): 1963-1971.
[13] Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience [J]. J Clin Oncol, 2006, 24(25): 4107-4115.
[14] Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes [J]. Exp Cell Res, 2009, 315(7): 1302-1312.
[15] Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy [J]. Circulation, 2004, 109(22): 2749-2754.
[16] Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib [J]. Clin Cancer Res, 2011, 17(10): 3490-3499.
[17] Van Hasselt JG, Boekhout AH, Beijnen JH, et al. Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity [J]. Clin Pharmacol Ther, 2011, 90(1): 126-132.
[18] Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J]. Circulation, 2006, 114(23): 2474-2481.
[19] Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J]. N Engl J Med, 2006, 354(8): 809-820.
[20] Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group(HeCOG) with biomarker evaluation [J]. Oncology, 2009, 76(4): 275-285.
[21] Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial [J]. J Clin Oncol, 2006, 24(18): 2773-2778.
[22] Costa RB, Kurra G, Greenberg L, et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer [J]. Ann Oncol, 2010, 21(11): 2153-2160.
[23] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med, 2006, 355(26): 2733-2743.